Comparative effectiveness of different treatment pathways for opioid use disorder.

Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data

Quan, H., Sundararajan, V., Halfon, P., Fong, A., Burnand, B., Luthi, J.-C., Saunders, L. D., Beck, C. A., Feasby, T. E., & Ghali, W. A. (2005) · Medical Care · doi:10.1097/01.mlr.0000182534.19832.83 · Cited by 10,669

Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies.

Sordo, L., Barrio, G., Bravo, M. J., Indave, B. I., Degenhardt, L., Wiessing, L., Ferri, M., & Pastor-Barriuso, R. (2017) · BMJ · doi:10.1136/bmj.j1550 · Cited by 1,816

Drug and Opioid-Involved Overdose Deaths — United States, 2013–2017

Scholl, L., Seth, P., Kariisa, M., Wilson, N. O., & Baldwin, G. T. (2018) · MMWR Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm675152e1 · Cited by 1,754

Medication for Opioid Use Disorder After Nonfatal Opioid Overdose and Association With Mortality: A Cohort Study

Larochelle, M. R., Bernson, D., Land, T., Stopka, T. J., Wang, N., Xuan, Z., Bagley, S. M., Liebschutz, J. M., & Walley, A. Y. (2018) · Annals of Internal Medicine · doi:10.7326/m17-3107 · Cited by 1,076

Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial

Lee, J. D., Nunes, E. V., Novo, P., Bachrach, K., Bailey, G. L., Bhatt, S., Farkas, S., Fishman, M., Gauthier, P., Hodgkins, C. C., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(17)32812-x · Cited by 700

Increases in Acute Hepatitis C Virus Infection Related to a Growing Opioid Epidemic and Associated Injection Drug Use, United States, 2004 to 2014

Zibbell, J. E., Asher, A. K., Patel, R. C., Kupronis, B. A., Iqbal, K., Ward, J. W., & Holtzman, D. J. (2017) · American Journal of Public Health · doi:10.2105/ajph.2017.304132 · Cited by 699

The triple wave epidemic: Supply and demand drivers of the US opioid overdose crisis

Ciccarone, D. (2019) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2019.01.010 · Cited by 677

National and state treatment need and capacity for opioid agonist medication-assisted treatment

Jones, C. M., Campopiano, M., Baldwin, G., & McCance-Katz, E. (2015) · American Journal of Public Health · doi:10.2105/ajph.2015.302664 · Cited by 668

Adjunctive Counseling During Brief and Extended Buprenorphine-Naloxone Treatment for Prescription Opioid Dependence: A 2-Phase Randomized Controlled Trial

Weiss, R. D. (2011) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2011.121 · Cited by 540

Medications for Opioid Use Disorder Save Lives

Mancher, M., & Leshner, A. (2019) · National Academies Press eBooks · doi:10.17226/25310 · Cited by 473

State Legislators’ Divergent Social Media Response to the Opioid Epidemic from 2014 to 2019: Longitudinal Topic Modeling Analysis

Stokes, D. C., Purtle, J., Meisel, Z. F., & Agarwal, A. K. (2021) · Journal of General Internal Medicine · doi:10.1007/s11606-021-06678-9 · Cited by 29

Treatment outcomes in individuals diagnosed with comorbid opioid use disorder and Posttraumatic stress disorder: A review

Meshberg‐Cohen, S., MacLean, R. R., Martin, A. M. S., Sofuoglu, M., & Petrakis, I. L. (2021) · Addictive Behaviors · doi:10.1016/j.addbeh.2021.107026 · Cited by 29

Discharges “Against Medical Advice” in Patients With Opioid-related Hospitalizations

Santos, C. J., Shofer, F. S., Lowenstein, M., & Perrone, J. (2020) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000000688 · Cited by 28

Beliefs about medications for opioid use disorder among Florida criminal problem-solving court & dependency court staff

Andraka‐Christou, B., & Atkins, D. N. (2020) · The American Journal of Drug and Alcohol Abuse · doi:10.1080/00952990.2020.1807559 · Cited by 28

African American/Black and Latino Adults with Detectable HIV Viral Load Evidence Substantial Risk for Polysubstance Substance Use and Co-occurring Problems: A Latent Class Analysis

Cleland, C. M., Gwadz, M. V., Collins, L. M., Wilton, L., Sherpa, D., Dorsen, C. G., Leonard, N. R., Cluesman, S. R., Martinez, B. Y., Ritchie, A. S., et al. (2021) · AIDS and Behavior · doi:10.1007/s10461-021-03212-0 · Cited by 28

The effect of medications for opioid use disorder (MOUD) on residential treatment completion and retention in the US

Stahler, G. J., & Mennis, J. L. (2020) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2020.108067 · Cited by 27

Examining differences in retention on medication for opioid use disorder: An analysis of Ohio Medicaid data

Zhang, P., Tossone, K., Ashmead, R., Bickert, T., Bailey, E., Doogan, N., Mack, A., Schmidt, S., & Bonny, A. E. (2021) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2021.108686 · Cited by 27

Developing a cascade of care for opioid use disorder among individuals in jail

Ray, B. R., Victor, G. A., Cason, R., Hamameh, N., Kubiak, S. P., Zettner, C., Dunnigan, M., Comartin, E. B., & Costello, M. (2022) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2022.108751 · Cited by 27

Identifying key risk factors for premature discontinuation of opioid use disorder treatment in the United States: A predictive modeling study

Stafford, C. A., Marrero, W. J., Naumann, R. B., Lich, K. H., Wakeman, S. E., & Jalali, M. S. (2022) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2022.109507 · Cited by 27

Estimated Costs and Outcomes Associated With Use and Nonuse of Medications for Opioid Use Disorder During Incarceration and at Release in Massachusetts

Chatterjee, A., Weitz, M., Savinkina, A. A., Macmadu, A., Madushani, R. W. M. A., Potee, R. A., Ryan, D., Murphy, S. M., Walley, A. Y., & Linas, B. P. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.7036 · Cited by 27

Overcoming Barriers to Prescribing Buprenorphine in the Emergency Department

Kim, H. S., & Samuels, E. A. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.4996 · Cited by 27

Global burden of amphetamine, cannabis, cocaine and opioid use in 204 countries, 1990–2023: a Global Burden of Disease Study

Kang, J., Kim, H. J., Kim, M. S., Collaborators, G. 2. S. U., Shin, J. I., Aalruz, H., Abate, Y. H., Abbas, N., Abbasian, M., ElHafeez, S. A., et al. (2026) · Nature Medicine · doi:10.1038/s41591-025-04137-0 · Cited by 26

Analysis of Stimulant Prescriptions and Drug-Related Poisoning Risk Among Persons Receiving Buprenorphine Treatment for Opioid Use Disorder

Mintz, C. M., Xu, K. Y., Presnall, N. J., Hartz, S. M., LEVIN, F. R., Scherrer, J. F., Bierut, L. J., & Grucza, R. A. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.11634 · Cited by 26

Variation in intervention stigma among medications for opioid use disorder

Madden, E. F., Barker, K. K., Guerra, J., Villanueva, C., & Sulzer, S. H. (2022) · SSM - Qualitative Research in Health · doi:10.1016/j.ssmqr.2022.100161 · Cited by 26

Mobile treatment for opioid use disorder: Implementation of community-based, same-day medication access interventions

Chatterjee, A., Baker, T. J., Rudorf, M., Walt, G., Stotz, C., Martin, A., Kinnard, E. N., McAlearney, A. S., Bosak, J., Medley, B., et al. (2023) · Journal of Substance Use and Addiction Treatment · doi:10.1016/j.josat.2023.209272 · Cited by 26

Medication for Addiction Treatment and Postpartum Health Care Utilization Among Pregnant Persons With Opioid Use Disorder

Ahrens, K. A., McBride, C. A., O’Connor, A. B., & Meyer, M. C. (2021) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000000827 · Cited by 25

Opioid agonist treatment initiation and linkage for hospitalized patients seen by a substance use disorder consultation service

Nordeck, C. D., Welsh, C., Schwartz, R. P., Mitchell, S. G., O’Grady, K. E., & Gryczynski, J. (2022) · Drug and Alcohol Dependence Reports · doi:10.1016/j.dadr.2022.100031 · Cited by 25

Patient- and Provider-Reported Experiences of a Mobile Novel Digital Therapeutic in People With Opioid Use Disorder (reSET-O): Feasibility and Acceptability Study

Kawasaki, S. S., Mills-Huffnagle, S. L., Aydinoglo, N., Maxin, H., & Nunes, E. V. (2022) · JMIR Formative Research · doi:10.2196/33073 · Cited by 23

Tailoring dissemination strategies to increase evidence-informed policymaking for opioid use disorder treatment: study protocol

Crable, E. L., Grogan, C. M., Purtle, J., Roesch, S. C., & Aarons, G. A. (2023) · Implementation Science Communications · doi:10.1186/s43058-023-00396-5 · Cited by 25

The Future of the United States Overdose Crisis: Challenges and Opportunities

Cerdá, M., Krawczyk, N., & Keyes, K. M. (2023) · Milbank Quarterly · doi:10.1111/1468-0009.12602 · Cited by 25

Initiation and Treatment Discontinuation of Medications for Opioid Use Disorder in Pregnant People Compared With Nonpregnant People

Xu, K. Y., Jones, H. E., Schiff, D. M., Martin, C. E., Kelly, J. C., Carter, E. B., Bierut, L. J., & Grucza, R. A. (2023) · Obstetrics and Gynecology · doi:10.1097/aog.0000000000005117 · Cited by 25

Caring for Our Patients With Opioid Use Disorder in the Perioperative Period: A Guide for the Anesthesiologist

Barreveld, A. M., Mendelson, A. M., Deiling, B. L., Armstrong, C. A., Viscusi, E. R., & Kohan, L. R. (2023) · Anesthesia & Analgesia · doi:10.1213/ane.0000000000006280 · Cited by 25

The substance use disorder treatment gap among US college students: Findings from the 2021 National Survey on Drug Use and Health

Pasman, E., Blair, L., Solberg, M. A., McCabe, S. E., Schepis, T., & Resko, S. M. (2024) · Drug and Alcohol Dependence Reports · doi:10.1016/j.dadr.2024.100279 · Cited by 24

Withdrawal during outpatient low dose buprenorphine initiation in people who use fentanyl: a retrospective cohort study

Jones, B. L. H., Geier, M., Neuhaus, J. M., Coffin, P. O., Snyder, H. R., Soran, C. S., Knight, K. R., & Suen, L. W. (2024) · Harm Reduction Journal · doi:10.1186/s12954-024-00998-9 · Cited by 24

Adapting Palliative Care Skills to Provide Substance Use Disorder Treatment to Patients With Serious Illness

Jones, K. F., Ho, J. J., Sager, Z. S., Childers, J. W., & Merlin, J. S. (2021) · American Journal of Hospice and Palliative Medicine® · doi:10.1177/1049909121999783 · Cited by 25

Inpatient Opioid Use Disorder Treatment by Generalists is Associated With Linkage to Opioid Treatment Programs After Discharge

Tierney, H. R., Rowe, C. L., Coffa, D. A., Sarnaik, S., Coffin, P. O., & Snyder, H. R. (2021) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000000851 · Cited by 24

The relationship between opioid agonist therapy satisfaction and fentanyl exposure in a Canadian setting

Mackay, L., Kerr, T. H., Fairbairn, N. S., Grant, C. C., Milloy, M., & Hayashi, K. (2021) · Addiction Science & Clinical Practice · doi:10.1186/s13722-021-00234-w · Cited by 24

The relationship between crystal methamphetamine use and methadone retention in a prospective cohort of people who use drugs

Mackay, L., Bach, P., Milloy, M., Cui, Z., Kerr, T. H., & Hayashi, K. (2021) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2021.108844 · Cited by 27

Attitudes toward Medication for Opioid Use Disorder among Substance Use Treatment Providers

Pasman, E., Lee, G., Kollin, R., Rodriguez, B., Agius, E., Madden, E. F., & Resko, S. M. (2022) · Substance Use & Misuse · doi:10.1080/10826084.2022.2115853 · Cited by 24

A scoping review of community-based post-opioid overdose intervention programs: implications of program structure and outcomes

Bailey, A., Harrington, C., & Evans, E. (2023) · Health & Justice · doi:10.1186/s40352-022-00201-w · Cited by 26

Trends in Methadone Dispensing for Opioid Use Disorder After Medicare Payment Policy Changes

Taylor, E. A., Cantor, J., Bradford, A. C., Simon, K. I., & Stein, B. D. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.14328 · Cited by 24

Racial and Ethnic Inequities in Buprenorphine and Methadone Utilization Among Reproductive-Age Women with Opioid Use Disorder: an Analysis of Multi-state Medicaid Claims in the USA

Xu, K. Y., Schiff, D. M., Jones, H. E., Martin, C. E., Kelly, J. C., Bierut, L. J., Carter, E. B., & Grucza, R. A. (2023) · Journal of General Internal Medicine · doi:10.1007/s11606-023-08306-0 · Cited by 24

Impact of Thyroid Status on Incident Kidney Dysfunction and Chronic Kidney Disease Progression in a Nationally Representative Cohort

You, A. S., Kalantar‐Zadeh, K., Brent, G. A., Narasaki, Y., Daza, A. C., Sim, J. J., Kovesdy, C. P., Nguyen, D. V., & Rhee, C. M. (2024) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2023.08.028 · Cited by 25

Economic modeling of reSET-O, a prescription digital therapeutic for patients with opioid use disorder

Wang, W., Lowe, N. G., Jalali, A., & Murphy, S. M. (2020) · Journal of Medical Economics · doi:10.1080/13696998.2020.1858581 · Cited by 24

A National Study of Homelessness, Social Determinants of Health, and Treatment Engagement Among Outpatient Medication for Opioid Use Disorder-Seeking Individuals in the United States

Gazzola, M. G., Carmichael, I. D., Christian, N. J., Zheng, X., Madden, L. M., & Barry, D. T. (2023) · Substance Abuse · doi:10.1177/08897077231167291 · Cited by 23

Prehospital Initiation of Buprenorphine Treatment for Opioid Use Disorder by Paramedics

Hern, H. G., Goldstein, D., Kalmin, M. M., Kidane, S., SHOPTAW, S. J., Tzvieli, O., & Herring, A. A. (2021) · Prehospital Emergency Care · doi:10.1080/10903127.2021.1977440 · Cited by 23

Recovery capital among people receiving treatment for opioid use disorder with buprenorphine

Parlier‐Ahmad, A. B., Terplan, M., Svikis, D. S., Ellis, L. P., & Martin, C. E. (2021) · Harm Reduction Journal · doi:10.1186/s12954-021-00553-w · Cited by 23

Effects of acute and repeated treatment with methocinnamox, a mu opioid receptor antagonist, on fentanyl self-administration in rhesus monkeys

Maguire, D. R., Gerak, L. R., Sanchez, J. J., Javors, M. A., Disney, A., Husbands, S. M., & France, C. P. (2020) · Neuropsychopharmacology · doi:10.1038/s41386-020-0698-8 · Cited by 23

Treatment for opioid use disorder in the Florida medicaid population: Using a cascade of care model to evaluate quality

Johnson, K., Hills, H. A., Ma, J., Brown, C. H., & McGovern, M. P. (2020) · The American Journal of Drug and Alcohol Abuse · doi:10.1080/00952990.2020.1824236 · Cited by 23

Cardiac Surgeons’ Treatment Approaches for Infective Endocarditis Based on Patients’ Substance Use History

Tiako, M. J. N., Mszar, R., Brooks, C., Mahmood, S. U. B., Mori, M., Geirsson, A., & Weimer, M. B. (2020) · Seminars in Thoracic and Cardiovascular Surgery · doi:10.1053/j.semtcvs.2020.11.031 · Cited by 23

Familial perceptions of appropriate treatment types and goals for a family member who has opioid use disorder

Nayak, S. M., Huhn, A. S., Bergeria, C. L., Strain, E. C., & Dunn, K. E. (2021) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2021.108649 · Cited by 24

Anxiety and Fear Avoidance Beliefs and Behavior May Be Significant Risk Factors for Chronic Opioid Analgesic Therapy Reliance for Patients with Chronic Pain—Results from a Preliminary Study

Silva, M. J., Coffee, Z. H., Yu, C. H., & Martel, M. O. (2021) · Pain Medicine · doi:10.1093/pm/pnab069 · Cited by 24

Multimorbidity and Inpatient Utilization Among Older Adults with Opioid Use Disorder in New York City

Han, B. H., Tuazon, E. D., Wei, M. Y., & Paone, D. (2021) · Journal of General Internal Medicine · doi:10.1007/s11606-021-07130-8 · Cited by 25

American College of Preventive Medicine: Addressing the Opioid Epidemic Through a Prevention Framework

Livingston, C. J., Berenji, M., Titus, T. M., Caplan, L. S., Freeman, R. J., Sherin, K. M., Mohammad, A., & Salisbury‐Afshar, E. (2022) · American Journal of Preventive Medicine · doi:10.1016/j.amepre.2022.04.021 · Cited by 24

The Health and Health Needs of People under Community Supervision

Hawks, L. C., Horton, N., & Wang, E. A. (2022) · The Annals of the American Academy of Political and Social Science · doi:10.1177/00027162221119661 · Cited by 25

Correlates of recent overdose among people who inject drugs in the San Diego/Tijuana border region

Bailey, K., Abramovitz, D. A., Patterson, T. L., Vera, A., Vera, C. F., Rangel, M. G., Friedman, J. R., Davidson, P. J., Bourgois, P. I., & Strathdee, S. A. (2022) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2022.109644 · Cited by 22

“A Lack of Empathy:” A qualitative study of Black people seeking treatment for opioid use disorder

Khatri, U. G., Tiako, M. J. N., Gebreyesus, A., Reid, A., Jacoby, S. F., & South, E. C. (2023) · SSM - Qualitative Research in Health · doi:10.1016/j.ssmqr.2023.100298 · Cited by 23

Economic Evaluation of Extended-Release Buprenorphine for Persons With Opioid Use Disorder

Flam-Ross, J. M., Marsh, E., Weitz, M., Savinkina, A., Schackman, B. R., Wang, J., Madushani, R. W. M. A., Morgan, J. R., Barocas, J. A., Walley, A. Y., et al. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.29583 · Cited by 21

Predictors of Initiation of Medication for Opioid Use Disorder and Retention in Treatment Among U.S. Pregnant Women, 2013–2017

Nguemeni Tiako, M. J., Friedman, A., Culhane, J., South, E., & Meisel, Z. F. (2021) · Obstetrics & Gynecology · doi:10.1097/aog.0000000000004307 · Cited by 21

Severe Maternal Morbidity Among Pregnant People With Opioid Use Disorder Enrolled in Medicaid

Auty, S. G., Frakt, A. B., Shafer, P. R., Stein, M. D., & Gordon, S. H. (2025) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.53303 · Cited by 21

Evaluation of Resident Physicians’ Knowledge of and Attitudes Towards Prescribing Buprenorphine for Patients With Opioid Use Disorder

Shuey, B., Lee, D. C., Ugalde, I. C., Borgan, S., Bresnan, C., Qureshi, M., Mhaskar, R. S., & Oxner, A. Z. (2020) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000000750 · Cited by 21

Therapeutic Approaches to Opioid Use Disorder: What is the Current Standard of Care?

Carley, J. A., & Oesterle, T. (2021) · International Journal of General Medicine · doi:10.2147/ijgm.s295461 · Cited by 21

Methadone vs. Buprenorphine for In-Hospital Initiation: Which Is Better for Outpatient Care Retention in Patients with Opioid Use Disorder?

Kessler, S., Schwarz, E. S., & Liss, D. B. (2021) · Journal of Medical Toxicology · doi:10.1007/s13181-021-00858-z · Cited by 21

Piloting a statewide emergency department take‐home naloxone program: Improving the quality of care for patients at risk of opioid overdose

Dora‐Laskey, A., Kellenberg, J. E., Dahlem, C. H., English, E., Walker, M., Brummett, C. M., & Kocher, K. E. (2021) · Academic Emergency Medicine · doi:10.1111/acem.14435 · Cited by 21

Inconsistencies between national drug policy and professional beliefs about psychoactive drugs among psychiatrists in the United States

Levin, A. W., Nagib, P. B., Deiparine, S., Gao, T. Z., Mitchell, J. J., & Davis, A. K. (2022) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2022.103816 · Cited by 21

Sorting through life: evaluating patient-important measures of success in a medication for opioid use disorder (MOUD) treatment program

Reed, M. K., Smith, K. R., Ciocco, F., Hass, R. W., Cox, A. L., Kelly, E. L., & Weinstein, L. C. (2023) · Substance Abuse Treatment Prevention and Policy · doi:10.1186/s13011-022-00510-1 · Cited by 21

Barriers and facilitators to the use of medication for opioid use disorder within the criminal justice system: Perspectives from clinicians

Booty, M. D., Harp, K. L. H., Batty, E. J., Knudsen, H. K., Staton, M., & Oser, C. B. (2023) · Journal of Substance Use and Addiction Treatment · doi:10.1016/j.josat.2023.209051 · Cited by 21

Barriers to retention in medications for opioid use disorder treatment in real-world practice

Villamil, V. I., Underwood, N. L., Cremer, L. J., Rooks-Peck, C. R., Jiang, X., & Guy, G. P. (2024) · Journal of Substance Use and Addiction Treatment · doi:10.1016/j.josat.2024.209310 · Cited by 21

Linkage facilitation for opioid use disorder in criminal legal system contexts: a primer for researchers, clinicians, and legal practitioners

Satcher, M. F., Belenko, S. R., Coetzer-Liversage, A., Wilson, K. J., McCart, M. R., Drazdowski, T. K., Fallin‐Bennett, A., Zaller, N. D., Schultheis, A. M., Hogue, A., et al. (2024) · Health & Justice · doi:10.1186/s40352-024-00291-8 · Cited by 25

Ecological momentary assessment and cue-elicited drug craving as primary endpoints: study protocol for a randomized, double-blind, placebo-controlled clinical trial testing the efficacy of a GLP-1 receptor agonist in opioid use disorder

Freet, C. S., Evans, B., Brick, T. R., Deneke, E., Wasserman, E. J., Ballard, S. M., Stankoski, D. M., Kong, L., Raja-Khan, N. T., Nyland, J. E., et al. (2024) · Addiction Science & Clinical Practice · doi:10.1186/s13722-024-00481-7 · Cited by 21

Toward a Typology of Office-based Buprenorphine Treatment Laws: Themes From a Review of State Laws

Andraka‐Christou, B., Gordon, A. J., Bouskill, K., Smart, R., Golan, O. K., Golan, M., Totaram, R., & Stein, B. D. (2021) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000000863 · Cited by 20

An examination between treatment type and treatment retention in persons with opioid and co-occurring alcohol use disorders

Mintz, C. M., Presnall, N. J., Xu, K. Y., Hartz, S. M., Sahrmann, J. M., Bierut, L. J., & Grucza, R. A. (2021) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2021.108886 · Cited by 21

Beyond state scope of practice laws for advanced practitioners: Additional supervision requirements for buprenorphine prescribing

Andraka‐Christou, B., Gordon, A. J., Spetz, J., Totaram, R., Golan, M., Golan, O. K., Harrison, J. M., Calder, S. G., Kertesz, S. G., & Stein, B. D. (2022) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2021.108715 · Cited by 20

Non-fatal overdose risk during and after opioid agonist treatment: A primary care cohort study with linked hospitalisation and mortality records

Domzaridou, E., Carr, M., Webb, R. T., Millar, T., & Ashcroft, D. M. (2022) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2022.100489 · Cited by 20

Opioids and Opioid Use Disorder in Pregnancy

Sanjanwala, A. R., Lim, G., & Krans, E. E. (2023) · Obstetrics and Gynecology Clinics of North America · doi:10.1016/j.ogc.2022.10.015 · Cited by 20

Perceptions around medications for opioid use disorder among a diverse sample of U.S. adults

Jaffe, K., Slat, S., Chen, L., Macleod, C., Bohnert, A. S. B., & Lagisetty, P. (2024) · Journal of Substance Use and Addiction Treatment · doi:10.1016/j.josat.2024.209361 · Cited by 20

Payment-related barriers to medications for opioid use disorder: A critical review of the literature and real-world application

Bowser, D., Bohler, R., Davis, M. T., Hodgkin, D., & Horgan, C. (2024) · Journal of Substance Use and Addiction Treatment · doi:10.1016/j.josat.2024.209441 · Cited by 19

Associations of retention on buprenorphine for opioid use disorder with patient characteristics and models of care in the primary care setting

Bailey, S. R., Lucas, J., Angier, H. E., Cantone, R. E., Fleishman, J., Garvey, B., Cohen, D. J., Rdesinski, R. E., & Gordon, L. (2021) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2021.108548 · Cited by 20

Pain Management Considerations in Patients With Opioid Use Disorder Requiring Critical Care

Smith, K., Wang, M., Abdukalikov, R., McAuliffe, A., Whitesell, D., Richard, J. M., Sauer, W. J., & Quaye, A. (2021) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.1999 · Cited by 19

Short communication: Relationship between social determinants and opioid use disorder treatment outcomes by gender

Parlier‐Ahmad, A. B., Radic, M., Svikis, D. S., & Martin, C. E. (2022) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2022.109337 · Cited by 19

Expanding access to medications for opioid use disorder through locally-initiated implementation

Wyse, J. J. B., Mackey, K., Lovejoy, T. I., Kansagara, D. L., Tuepker, A., Gordon, A. J., Korthuis, P. T., Herreid-O’Neill, A., Williams, B. E., & Morasco, B. J. (2022) · Addiction Science & Clinical Practice · doi:10.1186/s13722-022-00312-7 · Cited by 19

Addressing buprenorphine bottlenecks in the context of MAT Act implementation: A shared responsibility

Ostrach, B. M. M., Hill, L. G., Carpenter, D. M., & Pollini, R. A. (2023) · Journal of the American Pharmacists Association · doi:10.1016/j.japh.2023.04.029 · Cited by 19

Ambivalence and contingencies: A qualitative examination of peer recovery coaches' attitudes toward medications for opioid use disorder

Pasman, E., O’Shay, S., Brown, S., Madden, E. F., Agius, E., & Resko, S. M. (2023) · Journal of Substance Use and Addiction Treatment · doi:10.1016/j.josat.2023.209121 · Cited by 19

Medications for Opioid Use Disorder for Youth: Patient, Caregiver, and Clinician Perspectives

Buchholz, C., Bell, L. A., Adatia, S., Bagley, S. M., Wilens, T. E., Nurani, A., & Hadland, S. E. (2023) · Journal of Adolescent Health · doi:10.1016/j.jadohealth.2023.08.047 · Cited by 21

Managing Opioid Withdrawal Symptoms During the Fentanyl Crisis: A Review

Weber, A. N., Trebach, J. D., Brenner, M., Thomas, M. A., & Bormann, N. L. (2024) · Substance Abuse and Rehabilitation · doi:10.2147/sar.s433358 · Cited by 19

A mixed-methods approach to understanding overdose risk-management strategies among a nationwide convenience sample

Victor, G. A., Strickland, J. C., Kheibari, A., & Flaherty, C. W. (2020) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2020.102973 · Cited by 18

Naloxone provision to emergency department patients recognized as high-risk for opioid use disorder

Lane, B. H., Lyons, M. S., Stolz, U., Ancona, R. M., Ryan, R. J., & Freiermuth, C. E. (2020) · The American Journal of Emergency Medicine · doi:10.1016/j.ajem.2020.10.061 · Cited by 18

Looking beyond the opioid receptor: A desperate need for new treatments for opioid use disorder

Lee, Y. K., Gold, M. S., & Fuehrlein, B. (2021) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2021.120094 · Cited by 20

To Prescribe or Not to Prescribe?: Barriers and Motivators for Progressing Along Each Stage of the Buprenorphine Training and Prescribing Path

Winograd, R., Coffey, B., Woolfolk, C., Wood, C. A., Ilavarasan, V., Liss, D. B., Jain, S., & Stringfellow, E. J. (2022) · The Journal of Behavioral Health Services & Research · doi:10.1007/s11414-021-09783-z · Cited by 18

Medicaid professional fees for treatment of opioid use disorder varied widely across states and were substantially below fees paid by medicare in 2021

Clemans-Cope, L., Lynch, V., Payton, M., & Aarons, J. (2022) · Substance Abuse Treatment Prevention and Policy · doi:10.1186/s13011-022-00478-y · Cited by 18

Reluctant Saviors: Professional ambivalence, cultural imaginaries, and deservingness construction in naloxone provision

Baumgart-McFarland, M., Chiarello, E., & Slay, T. (2022) · Social Science & Medicine · doi:10.1016/j.socscimed.2022.115230 · Cited by 18

Estimating the impact of stimulant use on initiation of buprenorphine and extended-release naltrexone in two clinical trials and real-world populations

Cook, R., Foot, C. A., Arah, O. A., Humphreys, K. N., Rudolph, K. E., Luo, S. X., Tsui, J. I., Levander, X. A., & Korthuis, P. T. (2023) · Addiction Science & Clinical Practice · doi:10.1186/s13722-023-00364-3 · Cited by 18

Measurement Approaches to Estimating Methadone Continuity in Opioid Use Disorder Care

Busch, A. B., Kennedy‐Hendricks, A., Schilling, C. J., Stuart, E. A., Hollander, M. A. G., Meiselbach, M. K., Barry, C. L., Huskamp, H. A., & Eisenberg, M. D. (2023) · Medical Care · doi:10.1097/mlr.0000000000001838 · Cited by 18

Characteristics, treatment patterns and retention with extended-release subcutaneous buprenorphine for opioid use disorder: A population-based cohort study in Ontario, Canada

Iacono, A., Wang, T., Tadrous, M., Campbell, T. J., Kolla, G., Leece, P., Sproule, B. A., Kleinman, R. A., Besharah, J., Munro, C., et al. (2023) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2023.111032 · Cited by 18

Knowledge, Attitudes, and Beliefs About Opioid Use Disorder Treatment in Primary Care

del Pozo, B., Park, J. N., Taylor, B. G., Wakeman, S. E., Ducharme, L. J., Pollack, H. A., & Rich, J. D. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.19094 · Cited by 18

A comparison of office-based buprenorphine treatment outcomes in Bronx community clinics before versus during the COVID-19 pandemic

Cunningham, C. O., Khalid, L., Deng, Y., Torres‐Lockhart, K., Masyukova, M., Thomas, S., Zhang, C., & Lu, T. Y. (2021) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2021.108641 · Cited by 18

‘Not at all what I had expected’: Discontinuing treatment with extended-release naltrexone (XR-NTX): A qualitative study

Brenna, I. H., Marciuch, A., Birkeland, B., Veseth, M., Røstad, B. K., Løberg, E., Solli, K. K., Tanum, L., & Weimand, B. M. (2021) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2021.108667 · Cited by 18

Fentanyl overdose concerns among people who inject drugs: The role of sex, racial minority status, and overdose prevention efforts.

Jones, A. A., Schneider, K. E., Mahlobo, C. T., Maggs, J. L., Dayton, L., Tobin, K. E., & Latkin, C. A. (2022) · Psychology of Addictive Behaviors · doi:10.1037/adb0000834 · Cited by 18

Relative Cost Differences of Initial Treatment Strategies for Newly Diagnosed Opioid Use Disorder

Larochelle, M. R., Wakeman, S. E., Ameli, O., Chaisson, C. E., McPheeters, J., Crown, W. H., Azocar, F., & Sanghavi, D. M. (2020) · Medical Care · doi:10.1097/mlr.0000000000001394 · Cited by 17

A Bridge Too Far? Distance to Waivered Physicians and Utilization of Buprenorphine Treatment for Opioid use Disorder in West Virginia Medicaid

Saloner, B. K., Landis, R. K., Jayakrishnan, R., Stein, B. D., & Barry, C. L. (2022) · Substance Abuse · doi:10.1080/08897077.2021.1986882 · Cited by 17

Real‐world effectiveness of pharmacological treatments of opioid use disorder in a national cohort

Heikkinen, M., Taipale, H. T., Tanskanen, A. J., Mittendorfer‐Rutz, E., Lähteenvuo, M., & Tiihonen, J. (2022) · Addiction · doi:10.1111/add.15814 · Cited by 19

Opioid Use Disorder Diagnosis and Management

Wakeman, S. E. (2022) · NEJM Evidence · doi:10.1056/evidra2200038 · Cited by 17

Risk of Experiencing an Overdose Event for Patients Undergoing Treatment With Medication for Opioid Use Disorder

Brandt, L., Hu, M., Liu, Y., Castillo, F., Odom, G., Balise, R. R., Feaster, D. J., Nunes, E. V., & Luo, S. X. (2023) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20220312 · Cited by 17

Opioid Maintenance Therapy: A Review of Methadone, Buprenorphine, and Naltrexone Treatments for Opioid Use Disorder

Fipps, D. C., Oesterle, T., & Kolla, B. P. (2024) · Seminars in Neurology · doi:10.1055/s-0044-1787571 · Cited by 16

Missed Opportunities to Save Lives—Treatments for Opioid Use Disorder After Overdose

Schoenfeld, E. M., Westafer, L. M., & Soares, W. E. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.6369 · Cited by 17

Care cascade for patients with opioid use disorder and serious injection related infections

Upadhyaya, A., Marks, L. R., Schwarz, E. S., Liang, S. Y., Durkin, M. J., & Liss, D. B. (2021) · Toxicology Communications · doi:10.1080/24734306.2020.1869899 · Cited by 17

Black clients in expansion states who used opioids were more likely to access medication for opioid use disorder after ACA implementation

Johnson, N. L., Choi, S., & Herrera, C. (2021) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2021.108533 · Cited by 17

Potential barriers to filling buprenorphine and naltrexone prescriptions among a retrospective cohort of individuals with opioid use disorder

Morgan, J. R., Quinn, E. K., Chaisson, C. E., Ciemins, E. L., Stempniewicz, N., White, L. F., & Larochelle, M. R. (2021) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2021.108540 · Cited by 17

Increasing Access to Medications for Opioid Use Disorder in Primary Care: Removing the Training Requirement May Not Be Enough

Russell, H. A., Sanders, M., Meyer, J. K. V., Loomis, E., Mullaney, T., & Fiscella, K. A. (2021) · The Journal of the American Board of Family Medicine · doi:10.3122/jabfm.2021.06.210209 · Cited by 17

Opioid Use Disorder Among Ohio’s Medicaid Population: Prevalence Estimates From 19 Counties Using a Multiplier Method

Doogan, N., Mack, A., Wang, J., Crane, D. A., Jackson, R. D., Applegate, M., Villani, J., Chandler, R. K., & Barocas, J. A. (2022) · American Journal of Epidemiology · doi:10.1093/aje/kwac154 · Cited by 16

Treatment Pathways for Opioid Use Disorder in Commercially-Insured United States Adults from 2010-2019

Saini, J., Qato, D. M., Rizk, J. G., DiPaula, B. A., Ehret, M. J., Pathan, U., & Johnson, A. M. (2026) · Journal of Studies on Alcohol and Drugs · doi:10.15288/jsad.25-00480

Comparison of Rates of Overdose and Hospitalization After Initiation of Medication for Opioid Use Disorder in the Inpatient vs Outpatient Setting

Morgan, J. R., Barocas, J. A., Murphy, S. M., Epstein, R. L., Stein, M. D., Schackman, B. R., Walley, A. Y., & Linas, B. P. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.29676 · Cited by 40

Comparative study shows superiority of medications for opioid use disorder

(2020) · The Brown University Psychopharmacology Update · doi:10.1002/pu.30582

Real-world longitudinal treatment trajectories following opioid use disorder diagnosis among commercially insured beneficiaries in the United States

Rizk, J. G., Qato, D. M., Saini, J., Pathan, U., DiPaula, B. A., Ehret, M. J., Johnson, A. M., & Li, Y. (2025) · Journal of Substance Use and Addiction Treatment · doi:10.1016/j.josat.2025.209858 · Cited by 1

Evaluation of medications used for opioid use disorder in emergency departments: A cross-sectional analysis of the 2020 National Hospital Ambulatory Medical Care Survey

Lee, S., Sun, L. L., & Vakkalanka, J. P. (2024) · The American Journal of Emergency Medicine · doi:10.1016/j.ajem.2024.05.015 · Cited by 4